Research Topics
Species | AMY BETH HEIMBERGERSummaryAffiliation: The University of Texas Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patientsWilliam Humphries
Department of Neurosurgery, The University of Texas M, d, Anderson Cancer Center, Houston, TX, USA
J Transl Med 7:92. 2009....- The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patientsAmy B Heimberger
University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Unit 422, Houston, TX 77230 1402, USA
Expert Opin Biol Ther 9:1087-98. 2009..Further therapeutic strategies and potential pitfalls of using this approach are discussed... 
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomasAmy B Heimberger
Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 14:5166-72. 2008..Our hypothesis is that only the most malignant gliomas have a prominent glioma-infiltrating Treg population that contributes to the immunosuppressive biology and that the presence of Tregs is a negative prognostic variable...
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patientsAmy B Heimberger
Department of Neurosurgery, University of Texas M D Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Clin Cancer Res 11:1462-6. 2005..We sought to determine whether glioblastoma multiforme expression of either overexpressed wild-type EGFR or the mutant EGFRvIII is an independent predictor of overall patient survival...- Mechanisms of action of rapamycin in gliomasAmy B Heimberger
Brain Tumor Center, Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Neuro Oncol 7:1-11. 2005.... - Loss of the AP-2alpha transcription factor is associated with the grade of human gliomasAmy B Heimberger
Department of Neurosurgery, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 11:267-72. 2005..The purpose of our study was to determine AP-2alpha expression distribution among grades of gliomas and any possible effect on prognosis... - Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumorsAmy B Heimberger
Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Clin Cancer Res 9:4247-54. 2003..In the study described here, we tested in mouse models a vaccine consisting of a peptide encompassing the tumor-specific mutated segment of EGFRvIII (PEP-3) conjugated to keyhole limpet hemocyanin [KLH (PEP-3-KLH)]... - Biphasic malignant meningioma: a comparative genomic hybridization studyA B Heimberger
Department of Neurosurgery, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Neuropathol 21:258-64. 2002..Furthermore, CGH showed that the histologically appearing low-grade fibroblastic component had not solely the characteristic alterations of a benign meningioma but had already progressed to an atypical meningioma... - Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?Amy B Heimberger
Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Unit 442, FC7 3021, Houston, TX 77030 4009, USA
Neuro Oncol 13:3-13. 2011.... - Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case studyAmy B Heimberger
Department of Neurosurgery, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
Neuro Oncol 10:98-103. 2008..In fact, the temozolomide-induced lymphopenia may prove to be synergistic with a peptide vaccine secondary to inhibition of regulatory T cells or their delayed recovery... - Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastomaJohn H Sampson
Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 28:4722-9. 2010..Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms... - Clinical applications of a peptide-based vaccine for glioblastomaCharles W Kanaly
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Box 3050, 220 Sands Building, Research Drive, Durham, NC 27710, USA
Neurosurg Clin N Am 21:95-109. 2010.... - Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine modelLing Yuan Kong
Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
Clin Cancer Res 16:2550-61. 2010..We hypothesized that WP1193, a novel inhibitor of STAT3 signaling, would enhance the antitumor activity of IFN-alpha against metastatic melanoma... - Topotecan enhances immune clearance of gliomasJun Wei
Department of Neurosurgery, Unit 442, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Cancer Immunol Immunother 58:259-70. 2009..Based on our data we conclude that drugs, such as topotecan, which cause up regulation of Fas on glioma cells can be potentially exploited with immunotherapy to enhance immune clearance of tumors via Fas signaling... - Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanomaAmy B Heimberger
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Neurosurgery 50:158-64; discussion 164-6. 2002.... - Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapyJustin T Jordan
Department of Neurosurgery, Unit 442, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Cancer Immunol Immunother 57:123-31. 2008.... - EGFRvIII-targeted vaccination therapy of malignant gliomaBryan D Choi
Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Brain Pathol 19:713-23. 2009..Additionally, the corresponding therapeutic outcomes observed in these studies lend credence to the potential role of peptide-based vaccination strategies among emerging antitumor immunotherapies in patients with malignant glioma... - Glioma-associated cancer-initiating cells induce immunosuppressionJun Wei
Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Clin Cancer Res 16:461-73. 2010.... - Immunotherapy for human glioma: innovative approaches and recent resultsS Farzana Hussain
University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
Expert Rev Anticancer Ther 5:777-90. 2005..This review will provide an overview of the juxtaposition of the immune system and CNS, and will discuss the most recent and ongoing immunotherapeutic clinical trials that are demonstrating promising results... - Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant gliomaJohn H Sampson
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Semin Immunol 20:267-75. 2008..The recurrence of EGFRvIII-negative tumors in our patients, however, highlights the need for targeting a broader repertoire of tumor-specific antigens... - An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiformeJohn H Sampson
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Mol Cancer Ther 8:2773-9. 2009..7 months (C.I.(95), 14.5-25.6). Overall median survival from time of histologic diagnosis was 22.8 months (C.I.(95), 17.5-29). This study establishes the EGFRvIII mutation as a safe and immunogenic tumor-specific target for immunotherapy... - Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic targetJulia A Barnett
Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 13:3559-67. 2007..To evaluate the viability of further research efforts targeting this antigen, we examined the expression of CYP1B1 in glial cell malignancies... - A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cellsLing Yuan Kong
Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 14:5759-68. 2008..We hypothesized that WP1066, a novel STAT3 blockade agent, has marked antitumor activity, even against the melanoma metastasis to brain, a site typically refractory to therapies... - Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathwayJun Wei
Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
Mol Cancer Ther 9:67-78. 2010..These findings indicate that cancer-initiating cells contribute to the immune evasion of GBM and that blockade of the STAT3 pathway has therapeutic potential... - The role of tregs in glioma-mediated immunosuppression: potential target for interventionWilliam Humphries
Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Neurosurg Clin N Am 21:125-37. 2010.... - Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa)Amy B Heimberger
Department of Surgery, Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 8:3496-502. 2002..On the basis of these observations, we believe that clinical trials of ZD1839 against brain tumors expressing EGFR are warranted, but that special consideration should be given to tumors that coexpress EGFRvIII... - The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responsesS Farzana Hussain
Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, P.O. Box 301402, Houston, TX 77230-1402, USA
Neuro Oncol 8:261-79. 2006..Furthermore, the presence of regulatory T cells may also contribute to the lack of effective immune activation against malignant human gliomas... - Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastomaChristopher E Pelloski
Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 12:3935-41. 2006..This study was conducted to determine whether any of these markers are associated with survival time and response to radiation in glioblastoma... - A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patientsS Farzana Hussain
Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 67:9630-6. 2007.... - The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomasMohamed Abou-Ghazal
Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 14:8228-35. 2008.... - A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cellsLing Yuan Kong
Department of Neurosurgery, Unit 442, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
Cancer Immunol Immunother 58:1023-32. 2009..These results suggest that WP1066 enhances T cell cytotoxicity against melanoma through inhibition of Tregs... - Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastomaChristopher E Pelloski
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 25:2288-94. 2007..We sought to evaluate the clinical significance of GBM subtypes as defined by EGFRvIII status... - Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastomaJohn H Sampson
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
Neuro Oncol 13:324-33. 2011..EGFRvIII-targeted vaccination induces patient immune responses despite therapeutic TMZ-induced lymphopenia and eliminates EGFRvIII-expressing tumor cells without autoimmunity... - Awake craniotomy for brain tumors near eloquent cortex: correlation of intraoperative cortical mapping with neurological outcomes in 309 consecutive patientsStefan S Kim
Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Neurosurgery 64:836-45; discussion 345-6. 2009..We report herein the results of a retrospective study of cortical mapping and subsequent clinical outcomes in a large series of patients... - Central nervous system cancers: Clinical Practice Guidelines in OncologySteven S Brem
J Natl Compr Canc Netw 3:644-90. 2005 - Altered adenosine-to-inosine RNA editing in human cancerNurit Paz
Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel
Genome Res 17:1586-95. 2007..Altered epigenetic control was recently shown to play a central role in oncogenesis. We suggest that A-to-I RNA editing may serve as an additional epigenetic mechanism relevant to cancer development and progression...
Research Grants
- Modulation of Microglia and T Cell Interactions in Malignant GliomaAmy Heimberger; Fiscal Year: 2007..By further delineating the mechanisms underlying the failure of the immune system to eradicate or suppress gliomas, we hope to improve the efficacy of future immunotherapy, increase longevity and quality of life of glioma patients. ..
- Modulation of Microglia and T Cell Interactions in Malignant GliomaAmy Heimberger; Fiscal Year: 2009..By further delineating the mechanisms underlying the failure of the immune system to eradicate or suppress gliomas, we hope to improve the efficacy of future immunotherapy, increase longevity and quality of life of glioma patients. ..
- Modulation of Microglia and T Cell Interactions in Malignant GliomaAMY BETH HEIMBERGER; Fiscal Year: 2010..By further delineating the mechanisms underlying the failure of the immune system to eradicate or suppress gliomas, we hope to improve the efficacy of future immunotherapy, increase longevity and quality of life of glioma patients. ..